The RB@PVA matrix demonstrated cytotoxicity against PC-3 prostate cancer cells, with an IC50 value of 1.19 μM compared to 2.49 μM for free RB, indicating enhanced efficacy. This evidence concerns the gene RB1 and prostate cancer.